HLB Pharmaceutical Decides 1.2 Trillion Won Rights Offering Massive 32.81% Dilution Risk and New Factory Investment for Mid to Long Term Growth
HLB Pharmaceutical has decided to raise approximately 120 billion KRW by issuing 10,762,332 registered common shares through a rights offering followed by a public offering. This massive capital increase corresponds to 32.81% of existing shares, inevitably leading to significant dilution of existing shareholder value.
The proceeds will be used for facility investment of 55 billion KRW, operating funds of 50 billion KRW, and debt repayment of 15 billion KRW. The facility funds will be invested in constructing a new plant in Hyangnam and acquiring equipment to expand production capacity from 300 million to 700 million tablets annually and improve cost ratios.
Operating funds of 25 billion KRW are allocated to long-acting injectable and improved new drug R&D, while another 25 billion KRW is for raw material purchases and outsourcing processing costs to strengthen R&D capabilities and production stability. Debt repayment funds of 15 billion KRW will be used to repay short-term borrowings from Woori Bank, improving the financial structure.
The largest shareholder HLB Life Science and related parties plan to subscribe only 50% of allocated shares, reducing their post-offering stake from 20.93% to 18.35%, raising concerns about management stability. Additionally, stock pledge loans by the largest shareholder and CEO pose potential risk factors.
The company plans to improve profitability through in-house production conversion to reduce cost ratios and CSO fee reductions, but generic drug price cuts and low operating profit margins (1.57% consolidated) remain ongoing challenges.
In April 2026, the company was fined 55.05 million KRW for violating food labeling and advertising regulations for albumin products, and an administrative disposition regarding the use of unregistered containers is ongoing, posing risks to consumer healthcare segment sales.
The auditor Samsung Accounting Corporation issued an unqualified audit opinion and assessed internal accounting controls as effective, but there is room for governance improvement due to delays in outside director appointments.
The company holds 581 treasury shares and has not disclosed any dividend plans. Its debt ratio of 33.56% consolidated is better than the industry average of 41.04%, while the current ratio of 189.59% is similar to the industry average.
It is not yet determined whether this offering will be subject to intensive review by the Financial Supervisory Service, and if selected, the schedule could be delayed. Additionally, if the stock price declines after the offering price is set, the total proceeds may decrease, potentially disrupting funding plans.
[AI Summary]HLB Pharmaceutical’s 1.2 trillion won rights offering causes 32.81% massive dilution, putting short-term downward pressure on the stock price, but the new factory investment and R&D expansion are positive for mid to long-term growth drivers. However, low profitability structure, regulatory risks, and weakening management control are key risk factors for investors.
KOSDAQ Filing Information
[Correction of Description] Securities Registration Statement (Equity Securities)